Reply:
Vietnam is one of the fastest growing country in SouthEast Asia. Economic growth correlates with commitment to healthcare improvements. This is why its pharmaceutical industry is amongst the most dynamic ones in the world. The Vietnamese pharmaceutical market was worth USD 5,2 billion in August 2020 with a growth rate of 12% per year. The government is massively investing into the Pharmaceutical and Biomedical sector, followed with a strong desire from the population to make Vietnam healthier. The vietnamese rapid growth in demand for improved healthcare services and drugs naturally led to the introduction of clinical research and trials. Currently, there are 120 clinical trials involving at least one research site in the country.
Moreover, Vietnam provides a large pool of participants for clinical trials among its 95 million inhabitants. A part of the vietnamese population is, in fact, struggling with precarious health conditions. This added to the attractiveness of fincancial compensation allows pharmaceutical companies to conduct low-cost clinical trials. However, the country has a lot of skilled doctors and medical practitioners, who are entrusted with the population and can encourage vietnamese to involve in clinical research. The country’s research infrastructure is recent but rapidly evolving, and the MOH (Ministry of Health) made of developing these sites one of its priorities.
Clinical Research in Vietnam offers many opportunities that top global pharmaceutical companies such as AstraZeneca, Novartis, Roche or Bayer have already seized.